<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910503</url>
  </required_header>
  <id_info>
    <org_study_id>CREUZOT PRME 2019</org_study_id>
    <nct_id>NCT04910503</nct_id>
  </id_info>
  <brief_title>Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema</brief_title>
  <acronym>EMMA</acronym>
  <official_title>Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic macular oedema (DME) is the main cause of visual impairment (or visual acuity) in&#xD;
      patients with diabetic retinopathy, as it leads to progressive thickening of the retina,&#xD;
      which in the long term leads to progressive death of the photoreceptor cells. It is therefore&#xD;
      important to continue to treat macular oedema that has been progressing for several months or&#xD;
      even years (resistant DME).&#xD;
&#xD;
      The management of DME necessarily involves controlling diabetes (improving glycated&#xD;
      haemoglobin levels) and blood pressure, but this is often not enough.&#xD;
&#xD;
      Thus, when DME is significant and leads to a decrease in visual acuity, treatments are&#xD;
      administered directly into the eye (intravitreal injections). For some years now,&#xD;
      corticosteroids have been injected into the vitreous body (the gel that fills the eyeball)&#xD;
      through the white of the eye for their anti-inflammatory properties. Indeed, these drugs&#xD;
      improve the permeability of the retinal vessels and thus reduce oedema. These intravitreal&#xD;
      implants are most often used in patients who have already undergone cataract surgery&#xD;
      (pseudophakic) because corticosteroids also tend to aggravate a cataract. Currently, there&#xD;
      are two implants containing corticosteroids that can be injected: the dexamethasone implant&#xD;
      and the fluocinolone acetonide implant. These two implants have different properties,&#xD;
      particularly with regard to their duration of action.&#xD;
&#xD;
      Today, the overall management at 3 years and the quality of life associated with the&#xD;
      treatments deserve to be evaluated.&#xD;
&#xD;
      This study is the first multicenter controlled trial comparing the two reference&#xD;
      corticosteroid treatments in terms of overall cost of treatment and follow-up and patient&#xD;
      quality of life, while considering their efficacy and side effects. This evaluation will make&#xD;
      it possible to precisely define the respective place of each implant in the management of&#xD;
      resistant DME.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2027</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cost per healthy year gained</measure>
    <time_frame>3 years after starting treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Usual strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Innovative strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone intravitreal implant</intervention_name>
    <description>Implant every 4 months if necessary</description>
    <arm_group_label>Usual strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluocinolone Acetonide Intravitreal Implant</intervention_name>
    <description>Implantation</description>
    <arm_group_label>Innovative strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria*:&#xD;
&#xD;
          -  Patient who has given free, written and informed consent;&#xD;
&#xD;
          -  Major patient ;&#xD;
&#xD;
          -  Patient with treated DME greater than 300 microns in thickness that is still present&#xD;
             after at least 2 years of treatment and responsible for a decrease in visual activity&#xD;
             (BAV, Boath Audio Visual &lt; 6/10);&#xD;
&#xD;
          -  Patient who has received at least one anatomically and functionally effective&#xD;
             dexamethasone (DXM) injection more than 5 months ago; or one anti-VEGF injection more&#xD;
             than 3 months ago&#xD;
&#xD;
          -  Pseudophakic patient with surgery older than 6 months.&#xD;
&#xD;
          -  Patient with uni or bilateral diabetic macular oedema (in the case of bilateral&#xD;
             diabetic macular oedema, the most affected eye will be treated).&#xD;
&#xD;
        Exclusion criteria*:&#xD;
&#xD;
          -  Patient not covered by national health insurance;&#xD;
&#xD;
          -  Patient under a measure of legal protection;&#xD;
&#xD;
          -  Pregnant, parturient or breast-feeding woman;&#xD;
&#xD;
          -  Patient of full age who is unable to give consent;&#xD;
&#xD;
          -  Patient who has already participated in the study&#xD;
&#xD;
          -  Patient for whom the follow-up imposed by the protocol is not feasible (relocation)&#xD;
&#xD;
          -  Patients with a known hypersensitivity to the active substance or to one of the&#xD;
             excipients of Ozurdex®, Iluvien® ; Patients with uveitis or a severe form of asthma&#xD;
&#xD;
          -  Patients with pre-existing uveitis or glaucoma or active or suspected ocular or&#xD;
             periocular infection, including most viral diseases of the cornea and conjunctiva,&#xD;
             including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia,&#xD;
             varicella, mycobacterial infections, and mycoses&#xD;
&#xD;
          -  Glycated hemoglobin &gt; 12%.&#xD;
&#xD;
          -  In the study eye:&#xD;
&#xD;
          -  Patient with untreated severe proliferative or non-proliferative diabetic retinopathy;&#xD;
&#xD;
          -  Patient with pan-retinal photocoagulation or focal treatment less than 3 months old;&#xD;
&#xD;
          -  Patient with capillary macro aneurysms accessible to focal laser&#xD;
&#xD;
          -  Patient with ocular hypertonia &gt; 21 mmHg requiring a treatment of more than 2&#xD;
             molecules;&#xD;
&#xD;
          -  Aphakic patients or patients with a history of capsule rupture and iridal or&#xD;
             transcleral fixation implants&#xD;
&#xD;
          -  Phakic patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Catherine CREUZOT-GARCHER</last_name>
    <phone>03.80.29.51.73</phone>
    <email>catherine.creuzot-garcher@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Dijon-Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21 000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine CREUZOT-GARCHER</last_name>
      <phone>03.80.29.51.73</phone>
      <email>catherine.creuzot-garcher@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Fluocinolone Acetonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

